Doctor delivers chronic heart failure presentation

PHOTO PROVIDED Raj Patel, M.D., left, president of the Lock Haven Hospital medical staff, and Eldrin Lewis, M.D., MPH, are seen following Lewis’s recent presentation on chronic heart failure.

LOCK HAVEN — “Chronic Heart Failure: New Therapeutic Options for Improving Patient Outcomes” was the topic of Eldrin F. Lewis, M.D., MPH, of the Brigham and Women’s Hospital, at a recent gathering of Lock Haven Hospital medical staff.

In the presentation, Dr. Lewis outlined the scope of the heart failure problem in the United States including:

r Current estimates show 5.7 million men and women in the United States have heart failure (HF).

r 825,000 new heart failure cases are reported annually.

r This is projected to increase by 46 percent from 2012 to 2030 resulting in 8 million people with HF.

r High rates of hospitalizations and re-hospitalizations are seen among heart failure patients.

r One in 9 deaths in 2009 included HF as a contributing cause.

r About half the patients who develop HF die within five years of diagnosis.

r The estimated direct and indirect costs of HF in the United States is $39.2 billion per year.

Dr. Lewis detailed the initial clinical evaluation process for heart failure patients and the treatment strategies that physicians can utilize. He also offered an overview of new and emerging therapeutic approaches to treatment of heart failure. Heart failure is an umbrella term used to describe a variety of chronic heart diseases.

Dr. Lewis covered the range of stages of increasing severity that heart failure patients may progress through, and the various functional classifications patients will fall into.

“Heart failure encompasses such a wide range of related illnesses, and Dr. Lewis was very informative about the variety of treatment options that are new and emerging that could benefit our patients,” said Raj Patel, M.D., president of the medical staff at Lock Haven Hospital. “These regular, continuing medical education programs offer our medical staff high-level insight into new treatment options that can have a major impact on our patients and the treatment we provide to them.”